As­traZeneca un­veils pos­i­tive Phase 3 da­ta to move Imfinzi in­to ear­li­er stages of lung can­cer

As­traZeneca is mov­ing its block­buster can­cer drug Imfinzi in­to ear­li­er stages of small cell lung can­cer, a dis­ease that has not seen in­no­va­tion in stan­dard of care for four decades.

Tout­ing topline da­ta from its Phase 3 ADRI­AT­IC tri­al on Fri­day, As­traZeneca said Imfinzi demon­strat­ed a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in the co-pri­ma­ry end­points of over­all sur­vival and pro­gres­sion-free sur­vival.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.